Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease.

The Cochrane Database of Systematic Reviews
S AppletonJ Muhammad

Abstract

Chronic obstructive pulmonary disease (COPD) is a condition associated with high morbidity, mortality and cost to the community. Patients often report symptomatic improvement with short-acting beta-2 agonists (SABA) and anticholinergic bronchodilator medications, and both are recommended in COPD guidelines. These medications have different mechanisms of action and therefore could have an additive effect when combined. To compare the relative efficacy and safety of regular long term use (at least four weeks) of ipratropium bromide and short- acting beta-2 agonist therapy in patients with stable COPD. The Cochrane Airways Group Specialised Register of Trials was searched. Bibliographies were checked to identify relevant cross-references. Drug companies were contacted for relevant trial data. The searches are current to August 2005. All randomised controlled trials comparing at least 4 weeks of treatment with an anticholinergic agent (ipratropium bromide) alone or in combination with a beta-2 agonist (short acting) versus the beta-2 agonist alone, delivered via metered dose inhaler or nebuliser, in non-asthmatic adult subjects with stable COPD. Data extraction and study quality assessment was performed independently by three revie...Continue Reading

References

Sep 1, 1992·The American Review of Respiratory Disease·M NisarP M Calverley
Dec 1, 1989·British Journal of Clinical Pharmacology·B J LipworthD G McDevitt
Jan 1, 1986·The American Review of Respiratory Disease·N R AnthonisenJ E Hodgkin
Feb 1, 1982·Australian and New Zealand Journal of Medicine·R J PierceA H Campbell
Jan 1, 1984·Acta Clinica Belgica·P DejaegherJ Van der Veken
Jan 29, 1996·The American Journal of Medicine·D P TashkinS Sahn
Mar 1, 1996·American Journal of Respiratory and Critical Care Medicine·M J BelmanJ W Shin
Feb 1, 1996·Controlled Clinical Trials·A R JadadH J McQuay
Nov 1, 1996·Journal of Clinical Epidemiology·D A RedelmeierR S Goldstein
Jan 1, 1997·American Journal of Respiratory and Critical Care Medicine·D E O'DonnellK A Webb
Nov 17, 1998·American Journal of Respiratory and Critical Care Medicine·D E O'DonnellK A Webb
Aug 3, 1999·American Journal of Respiratory and Critical Care Medicine·D E O'DonnellK A Webb
Feb 16, 2000·Chest·G T Ferguson
Apr 12, 2002·Chest·Andrea RossiUNKNOWN Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group
Aug 28, 2002·Circulation·Jeffrey PlattUNKNOWN National Heart, Lung, and Blood Institute Heart and Lung Xenotransplantation Working Group
Jun 5, 2004·The European Respiratory Journal·S SpencerP W Jones

❮ Previous
Next ❯

Citations

Sep 15, 2006·Journal of General Internal Medicine·Douglas C McCrory
Nov 3, 2010·International Journal of Chronic Obstructive Pulmonary Disease·Davood AttaranReza Basiri
Aug 30, 2016·The Cochrane Database of Systematic Reviews·Wouter H van GeffenHuib A M Kerstjens
Jun 4, 2013·The Cochrane Database of Systematic Reviews·Emma J WelshPhillippa Poole
Jul 11, 2012·BMC Health Services Research·Emily J Henderson, Greg P Rubin
Feb 14, 2008·International Journal of Chronic Obstructive Pulmonary Disease·Alfredo PotenaAlberto Papi
Nov 13, 2015·QJM : Monthly Journal of the Association of Physicians·Graeme P Currie, Brian J Lipworth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.